+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and leukemia-reactive cytotoxic T-cells



A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and leukemia-reactive cytotoxic T-cells



Blood 102(11): 388a, November 16



Adoptive immunotherapy, using ex vivo generated and expanded CTLs can be effective in treating minimal residual disease. To determine the mechanisms by which adopive immunotherapy could reduce lethality to C1498 (acute myeloid leukemia (AML)) cells, a novel technique was developed to track, both leukemic blasts and adoptively transferred CTLs independently and simultaneously in vivo using whole body and confocal imaging techniques. Bone marrow-derived dendritic cells (DCs) were pulsed with AML lysates. Syngeneic splenocytes obtained from enhanced green fluorescent protein (eGFP) transgenic mice were co-cultured with DCs to prime AML reactive T-cells which were expanded by exposure to anti-CD3/CD28 mAb-coated magnetic microspheres. To track AML cells stable transfectants of C1498 expressing the red fluorescent protein DSRed2 were generated. Syngeneic mice were injected intravenously with a 100% lethal dose of C1498 (4X105/mouse). One day later ex vivo generated CTLs were injected intravenously. Migration, homing, and survival of adoptively transferred T-cells and AML cells were assessed. AML cells were widely metastatic and could be trafficked by whole-body imaging techniques. Three factors related to CTLs correlated with disease-free survival (DFS): 1) CTL dose: 5X106 versus 40X106 CTLs/mouse (p=0.04) with the higher dose resulting in up to a 50% DFS. The site of treatment failure was mainly the CNS where no CTLs could be identified. 2) Duration of ex vivo expansion (9 days versus 16 days, p=0.01). Short-term expanded CTLs could be found at high frequency in lymphoid organs for longer than 4 weeks after transfer whereas long term expanded CTLs were cleared from the system after 2 weeks. 3) L-selectin expression (L-selectin high fraction versus L-selectin low fraction, p=0.05) of CTLs fractionated prior to infusion. L-selectin low CTLs were only found in lymphoid organs at very low frequency and cleared rapidly from the organism, whereas the L-selectin high fraction homed readily to the lymph nodes, could be identified longer in non lymphoid organs and rescued up to 70% of mice. In sites of AML deposits, CTLs could be seen juxtaposed to AML cells which had a fragmented appearance. In summary, we have developed a new system in which CTLs and tumor cells can be simultaneously visualized in vivo and isolated based upon fluorescent properties. Such studies have provided insight as to the limitations of adoptive CTL transfer and should lead to new strategies to overcome tumor recurrence.

(PDF emailed within 1 workday: $29.90)

Accession: 034312399

Download citation: RISBibTeXText


Related references

A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Research 64(11): 3914-3921, 2004

Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. Biology of Blood and Marrow Transplantation 2(1): 31-36, 1996

Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo. Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres Dans les Recherches sur le Cancer 131: 223-238, 1993

Treatment of relapsed leukemia after allogeneic stem cell transplantation with in-vitro generated leukemia-reactive cytotoxic T cells. Blood 102(11): 981a-982a, November 16, 2003

In vitro induction of cell-mediated immunity to murine leukemia cells. II. cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures. Journal of Immunological Methods 16(1): 39-58, 1977

An In Vivo Mouse System To Analyze Migratory Properties of Different Subsets of Myeloid Leukemia Reactive CD8+ T Cells In Vivo. Blood 100(11): Abstract No 3238, November 16, 2002

Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential. Cellular Immunology 265(1): 23-30, 2010

Apoptosis in freshly isolated leukemia cells from patients with acute myeloblastic leukemia cells from patients with acute myeloblastic leukemia and chronic lymphocytic leukemia induced by cytotoxic anticancer drugs in relation to clinical response to chemotherapy. Annals of Hematology 73(SUPPL 2): A32, 1996

AML or CML dendritic cells for the in vitro generation of leukemia-reactive cytotoxic T cells. Blood 96(11 Part 1): 175a, November 16, 2000

Biological activity of cytotoxic dendritic cells cocultured with cytokine-induced killer cells and their effect on acute leukemia cells. Genetics and Molecular Research 14(4): 13208-13214, 2016

Studies on in-vivo priming of the trinitrophenyl-reactive cytotoxic effector-system. III. Are helper T cells involved in the in-vitro generation of cross-reactive as well as restricted cytotoxic responses?. Immunobiology 160(5): 472-478, 1982

Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. Blood 74(1): 343-353, 1989

Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells. Applied Radiation and Isotopes 110: 1-7, 2016

Monoclonal antibody against a differentiation antigen on human leukemia cells: cross-reactivity with rat leukemia and suppression of rat leukemia in vivo. Journal of Immunology 130(6): 2930-2936, 1983

Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo. Leukemia & Lymphoma 5(4): 263-271, 1991